Drug development against dementia based on understanding of molecular and cellular pathogenesis

DOI Web Site Web Site 14 References
  • Tomita Taisuke
    Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo

Bibliographic Information

Other Title
  • 認知症の分子細胞病態の解明と治療法の開発
  • ニンチショウ ノ ブンシ サイボウ ビョウタイ ノ カイメイ ト チリョウホウ ノ カイハツ

Search this article

Abstract

Pathological and molecular genetic analyses have revealed that amyloid-β peptide and tau protein are involved in the pathogenesis of Alzheimer disease (AD). Moreover, identification of cerebrospinal biomarker, advances in brain imaging and results of observational cohort studies indicate that AD is a chronic disease with abnormal protein metabolism in the brain. Current approaches targeting pathogenic molecules for AD have been developed as preventive medicine. In addition, abnormal protein aggregation is now recognized as a common pathological feature of neurodegenerative diseases that cause dementia. Thus, cellular pathologies in the brain along with the deposition of aggregated protein are highlighted as novel therapeutic key targets in the drug development.

Journal

  • Drug Delivery System

    Drug Delivery System 34 (5), 346-351, 2019-11-25

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References(14)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top